Shares of DIAGNOS Inc. (CVE:ADK – Get Free Report) were down 1% on Monday. The company traded as low as C$0.47 and last traded at C$0.47. Approximately 126,218 shares were traded during trading, a decline of 44% from the average daily volume of 227,176 shares. The stock had previously closed at C$0.48.
DIAGNOS Stock Up 1.1%
The firm’s 50-day moving average price is C$0.43 and its 200-day moving average price is C$0.30. The company has a market cap of C$57.49 million, a price-to-earnings ratio of -11.88 and a beta of 0.40. The company has a debt-to-equity ratio of 204.05, a current ratio of 1.49 and a quick ratio of 0.68.
Insiders Place Their Bets
In related news, Director Robert Dunn purchased 105,000 shares of the stock in a transaction that occurred on Friday, August 28th. The stock was purchased at an average cost of C$0.48 per share, for a total transaction of C$50,400.00. Following the acquisition, the director owned 2,679,920 shares in the company, valued at approximately C$1,286,361.60. This trade represents a 4.08% increase in their ownership of the stock. Over the last three months, insiders have acquired 433,571 shares of company stock worth $146,400. 16.81% of the stock is currently owned by corporate insiders.
About DIAGNOS
DIAGNOS Inc provides software-based services primarily in Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. The company offers healthcare services through Computer Assisted Retina Analysis, a web-based software tool that assists healthcare professionals for the detection of diabetic retinopathy; and allows eye care specialist to visualize both normal retinal landmarks and pathological changes. It also provides various consulting services in the fields of data analysis and artificial intelligence.
Further Reading
- Five stocks we like better than DIAGNOS
- Why Sticky Services Inflation Could Lift These 3 Stocks
- RPM International’s Dividend King Status Just Got Stronger
- The AI Boom’s Next Big Winners May Wear Hard Hats
- Rivian Escapes the EV Graveyard—But Can It Stay Alive?
Receive News & Ratings for DIAGNOS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DIAGNOS and related companies with MarketBeat.com's FREE daily email newsletter.